Story

Eli Lilly Named Top Pharma Pick by Jefferies on GLP-1 Drug Strength

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Eli Lilly Named Top Pharma Pick by Jefferies on GLP-1 Drug Strength
Text size
Background

Jefferies has named Eli Lilly (LLY) its top pick among large-cap pharmaceutical stocks, citing the company's powerful earnings momentum. Analyst Akash Tewari maintained a "Buy" rating and raised the firm's price target on the stock to $1,440, implying a potential upside of approximately 29% from its current price of $1,115.68.

Blockbuster Q2 Performance

The upgrade follows a robust second-quarter report from Eli Lilly, where the company significantly surpassed market expectations. Total revenue for the quarter reached approximately $23 billion, well ahead of the $20.7 billion consensus estimate. Earnings per share came in at $8.38, also beating the anticipated $6.68.

The strong results were fueled by the outperformance of its key GLP-1 drugs for diabetes and weight loss:

  • Mounjaro: Sales of $9.94 billion beat expectations by 12%.
  • Zepbound: Sales of $4.93 billion exceeded forecasts by 6%.
  • Foundayo (orforglipron): The company's new oral GLP-1 drug posted Q2 revenue of $98 million.

Raised Guidance and Analyst Outlook

Sample IUX Markets – In-articleAd

In response to the strong demand, Eli Lilly raised its full-year 2026 revenue guidance to a range of $85 billion to $87 billion, up from the previous forecast of $82 billion to $85 billion. Jefferies analyst Akash Tewari noted that he believes this revised guidance is still conservative, with his own model projecting revenue could reach $88.5 billion.

The analyst also highlighted Lilly's growing dominance in the market. The company's share of the international incretin market has reportedly increased to 54.9%, while its share of the U.S. incretin mimetic market stands at approximately 60.9%.

Market Catalysts and Sector-Wide Optimism

Several factors are contributing to the positive outlook. The implementation of the Medicare Bridge Program on July 1 is expected to add 20 million potentially eligible patients and increase U.S. insurance coverage for obesity treatments by about 35%. Additionally, Lilly's oral GLP-1 tablet, orforglipron (marketed as Foundayo), recently received approval in the U.K. for both weight management and Type 2 diabetes.

Other financial institutions have echoed this bullish sentiment. Following the earnings release, analysts at Wells Fargo and BMO Capital also raised their price targets on Eli Lilly. Bank of America reportedly increased its forecast for the total global obesity market, citing the strong international growth demonstrated by the company.

Read next

More on Stocks
Back to latest news

LATEST